Clinical Report: Musings from The Power List: Miguel Forte

Overview

Miguel Forte highlights the challenges of patient access in cell and gene therapy, emphasizing manufacturing capacity and reimbursement issues.

Background

Cell and gene therapy represents a rapidly evolving field with the potential to provide curative treatments for various diseases. However, significant barriers such as manufacturing capacity, clinical delivery, and reimbursement hinder patient access.

Data Highlights

No numerical or trial data was provided in the source material.

Key Findings

• Patient access is currently the greatest challenge in cell and gene therapy.
• Limited manufacturing capacity and reimbursement issues restrict treatment options.
• Allogeneic cell therapies, particularly those from iPSCs, are making significant progress.
• Operational changes are essential for advancing the field.

Clinical Implications

Healthcare professionals should be aware of the barriers to patient access in cell and gene therapy.

Conclusion

Miguel Forte discusses the importance of addressing current challenges in cell and gene therapy.

Related Resources & Content

1. FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease | FDA, 2026 -- FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
2. Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy - PubMed, 2023 -- Gene Therapy for Sickle Cell Disease: Practice Recommendations
3. the analytical scientist — Musings from the Power List: Gary Hieftje
4. the analytical scientist — The Emotive List?
5. the analytical scientist — A Future-Focused Power List
6. the analytical scientist — The 2023 Power List is Live!
7. Musings from the Power List: Gary Hieftje
8. The Emotive List?
9. A Future-Focused Power List
10. The 2023 Power List is Live!
11. FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease | FDA
12. Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy - PubMed